Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 485

1.

Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.

Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK.

Gynecol Oncol. 2009 Aug;114(2):219-24. doi: 10.1016/j.ygyno.2009.04.007. Epub 2009 May 17.

PMID:
19446868
2.

Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.

Gordinier ME, Dizon DS, Fleming EL, Weitzen S, Schwartz J, Parker LP, Granai CO.

Gynecol Oncol. 2006 Oct;103(1):72-4. Epub 2006 Feb 21.

PMID:
16494932
3.

Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.

Miolo G, Baldo P, Bidoli E, Lombardi D, Scalone S, Sorio R, Veronesi A.

Tumori. 2009 Nov-Dec;95(6):687-90.

4.

Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.

Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C.

Anticancer Drugs. 2008 Jun;19(5):541-5. doi: 10.1097/CAD.0b013e3282fcbbf7.

PMID:
18418221
5.

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.

Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E.

Oncology. 2006;70(2):141-6. Epub 2006 Apr 26.

PMID:
16645327
6.
7.

Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.

Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E.

Gynecol Oncol. 2008 Feb;108(2):332-5.

PMID:
18083217
8.

Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.

Steppan I, Reimer D, Sevelda U, Ulmer H, Marth C, Zeimet AG.

Chemotherapy. 2009;55(6):391-8. doi: 10.1159/000262452. Epub 2009 Nov 30.

PMID:
19955744
9.

Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.

Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J; Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO).

Anticancer Res. 2008 Mar-Apr;28(2B):1329-34.

10.

Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patients.

Ko EM, Lippmann Q, Caron WP, Zamboni W, Gehrig PA.

Gynecol Oncol. 2013 Dec;131(3):683-8. doi: 10.1016/j.ygyno.2013.09.031. Epub 2013 Oct 4.

PMID:
24096112
11.

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction.

Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman R, Kavanagh JJ.

Gynecol Oncol. 2007 Aug;106(2):375-80. Epub 2007 May 18.

PMID:
17512575
12.

A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.

Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.

Cancer Chemother Pharmacol. 2008 Apr;61(5):847-53. Epub 2007 Jul 4.

PMID:
17609947
13.

Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.

Julius JM, Tanyi JL, Nogueras-Gonzalez GM, Watkins JL, Coleman RL, Wolf JK, Smith JA.

Int J Gynecol Cancer. 2013 Feb;23(2):348-54. doi: 10.1097/IGC.0b013e31827c18f3.

14.

The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.

Martschick A, Sehouli J, Patzelt A, Richter H, Jacobi U, Oskay-Ozcelik G, Sterry W, Lademann J.

Anticancer Res. 2009 Jun;29(6):2307-13.

16.

Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome.

Mangana J, Zipser MC, Conrad C, Oberholzer PA, Cozzio A, Knuth A, French LE, Dummer R.

Eur J Dermatol. 2008 Sep-Oct;18(5):566-70. doi: 10.1684/ejd.2008.0490. Epub 2008 Aug 8.

PMID:
18693162
17.

Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx/Doxil).

Grenier N, Lebel V, Gill M, Mullen T, Mitchinson K, Sebborn K, Pouliot JF.

Can Oncol Nurs J. 2007 Summer;17(3):133-40. English, French.

PMID:
17944313
18.

Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.

Gorumlu G, Kucukzeybek Y, Kemal-Gul M, Karaca B, Cosan-Terek M, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R.

J BUON. 2008 Jul-Sep;13(3):349-52.

PMID:
18979548
19.

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

del Carmen MG, Micha J, Small L, Street DG, Londhe A, McGowan T.

Gynecol Oncol. 2012 Sep;126(3):369-74. doi: 10.1016/j.ygyno.2012.05.028. Epub 2012 May 30.

PMID:
22659190
20.

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Márquez A, Vicente D, García-Sáenz JA, Martín M.

Breast Cancer Res Treat. 2010 Jul;122(1):169-76. doi: 10.1007/s10549-010-0860-9. Epub 2010 Apr 2.

PMID:
20361253

Supplemental Content

Support Center